Angela Moore

Angela Moore supports the National Cancer Institute’s procurement mission by managing complex scientific and technical acquisitions aligned with the agency’s mission to accelerate cancer research and precision medicine innovation. She oversees contracts for high-capability research services, data infrastructure, and analytical platforms that enable genomic analysis, translational science, and laboratory modernization. Her acquisitions span professional scientific services, computing infrastructure, and custom software development, ensuring that NCI’s research ecosystem is equipped with cutting-edge capabilities to support national cancer priorities. Her primary contractor relationships center on Roche Diagnostics Corporation, reflecting a strong reliance on industry leaders in diagnostic technologies and life sciences instrumentation. She frequently engages with firms offering advanced data processing, bioinformatics solutions, and research support services, fostering partnerships that bridge commercial innovation with public health research needs. These relationships are characterized by long-term, performance-based contracting models that prioritize technical excellence, scalability, and compliance with federal research standards. Angela’s contracting portfolio is predominantly open competition, with 83.3% of awards issued under no set-aside, indicating a focus on technical merit and capability over socioeconomic preferences. However, she consistently allocates 16.7% of opportunities to total small business set-asides under FAR 19.5, demonstrating a measured but intentional commitment to small business participation in high-complexity scientific contracting. Her procurement focus is concentrated in NAICS 541990 (professional scientific services), 518210 (data infrastructure and cloud-based computing), and 541715 (research and development in life sciences). She regularly procures bioinformatics platforms, computational biology tools, custom data analytics systems, and research support services critical to genomic sequencing, molecular diagnostics, and translational oncology initiatives, reflecting deep expertise in the technical domains underpinning modern cancer research.